DD Support Board and Research Team

[dabullishbear]

Call GHS/ITOR where the clinical trials are being held. They had tested a lot more than 3 patients but could only bring 3 to completion due short supply of Prolanta. The drug is extremely expensive to manufacture and is probably the driving factor for bringing the company public to have access to more capital and equity. They had burned through $15m+ in venture capital up until this year.